VYNE Therapeutics Inc.

NasdaqCM:VYNE Voorraadrapport

Marktkapitalisatie: US$39.1m

VYNE Therapeutics Beheer

Beheer criteriumcontroles 2/4

VYNE Therapeutics' CEO is Dave Domzalski, appointed in Mar 2020, has a tenure of 4.67 years. total yearly compensation is $2.72M, comprised of 23.5% salary and 76.5% bonuses, including company stock and options. directly owns 3.37% of the company’s shares, worth $1.32M. The average tenure of the management team and the board of directors is 4.7 years and 3.6 years respectively.

Belangrijke informatie

Dave Domzalski

Algemeen directeur

US$2.7m

Totale compensatie

Percentage CEO-salaris23.5%
Dienstverband CEO4.7yrs
Eigendom CEO3.4%
Management gemiddelde ambtstermijn4.7yrs
Gemiddelde ambtstermijn bestuur3.6yrs

Recente managementupdates

Recent updates

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Oct 09
We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation

Apr 27
Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

May 04
We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

Aug 12

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

Jul 02
Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Mar 19
VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Jan 13

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Dec 03
VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13
Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

Jun 30

Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt

Jun 07
Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17
Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)

Feb 10
Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)

VYNE Therapeutics closes capital raise of $50M

Jan 29

Analyse CEO-vergoeding

Hoe is Dave Domzalski's beloning veranderd ten opzichte van VYNE Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$29m

Dec 31 2023US$3mUS$638k

-US$28m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$1mUS$638k

-US$34m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$40m

Mar 31 2022n/an/a

-US$42m

Dec 31 2021US$5mUS$638k

-US$44m

Sep 30 2021n/an/a

-US$59m

Jun 30 2021n/an/a

-US$69m

Mar 31 2021n/an/a

-US$226m

Dec 31 2020US$3mUS$501k

-US$256m

Sep 30 2020n/an/a

-US$270m

Jun 30 2020n/an/a

-US$269m

Mar 31 2020n/an/a

-US$120m

Dec 31 2019n/an/a

-US$95m

Sep 30 2019n/an/a

-US$71m

Jun 30 2019n/an/a

-US$64m

Mar 31 2019n/an/a

-US$63m

Dec 31 2018US$1mUS$440k

-US$74m

Sep 30 2018n/an/a

-US$77m

Jun 30 2018n/an/a

-US$80m

Mar 31 2018n/an/a

-US$77m

Dec 31 2017US$3mUS$417k

-US$66m

Compensatie versus markt: Dave's total compensation ($USD2.72M) is above average for companies of similar size in the US market ($USD655.02K).

Compensatie versus inkomsten: Dave's compensation has increased whilst the company is unprofitable.

CEO

Dave Domzalski (57 yo)

4.7yrs

Tenure

US$2,716,350

Compensatie

Mr. David T. Domzalski, also known as Dave, has been President, Chief Executive Officer and Director at VYNE Therapeutics Inc. (formerly known as Menlo Therapeutics Inc.). since March 9, 2020. Mr. Domzalsk...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
David Domzalski
CEO, President & Director4.7yrsUS$2.72m3.37%
$ 1.3m
Iain Stuart
Chief Scientific Officer4.7yrsUS$1.16m0.91%
$ 353.8k
Mutya Harsch
General Counsel4.7yrsUS$1.13m1.01%
$ 394.9k
Tyler Zeronda
CFO & Treasurer3.4yrsgeen gegevens0.89%
$ 348.7k
Subhashis Banerjee
Senior Vice President of Clinical Developmentless than a yeargeen gegevensgeen gegevens
Darrell Rigel
Consultant6yrsUS$115.20kgeen gegevens

4.7yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: VYNE's management team is considered experienced (4.7 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
David Domzalski
CEO, President & Director4.7yrsUS$2.72m3.37%
$ 1.3m
Sharon Surrey-Barbari
Independent Non Employee Director4.7yrsUS$116.10k0.0071%
$ 2.8k
Patrick LePore
Lead Independent Director4.2yrsUS$123.60k0.25%
$ 96.7k
Steven Basta
Director9.2yrsUS$83.60k0.051%
$ 19.7k
Anthony Bruno
Independent Non-Employee Director4.7yrsUS$101.10k0.013%
$ 5.0k
Elisabeth Sandoval-Little
Independent Director5.7yrsUS$108.60k0%
$ 0
Christine Borowski
Independent Directorless than a yeargeen gegevensgeen gegevens
Roy Fleischmann
Member of Scientific Advisory Board3.1yrsgeen gegevensgeen gegevens
Martin Okun
Member of Scientific Advisory Board3.1yrsgeen gegevensgeen gegevens
David Sachar
Member of Scientific Advisory Board3.1yrsgeen gegevensgeen gegevens
Olaf Stuve
Member of Scientific Advisory Board3.1yrsgeen gegevensgeen gegevens
Johnathan Whetstine
Member of Scientific Advisory Board3.1yrsgeen gegevensgeen gegevens

3.6yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: VYNE's board of directors are considered experienced (3.6 years average tenure).